| Literature DB >> 35630704 |
Ornchuma Naksuriya1, Krai Daowtak2, Singkome Tima3, Siriporn Okonogi1, Monika Mueller4, Stefan Toegel5, Ruttiros Khonkarn1,6.
Abstract
Cyrtosperma johnstonii is one of the most interesting traditional medicines for cancer treatment. This study aimed to compare and combine the biological activities related to cancer prevention of the flavonoid glycosides rutin (RT) and isorhamnetin-3-o-rutinoside (IRR) and their hydrolysis products quercetin (QT) and isorhamnetin (IR) from C.johnstonii extract. ABTS and MTT assays were used to determine antioxidant activity and cytotoxicity against various cancer cells, as well as normal cells. Anti-inflammatory activities were measured by ELISA. The results showed that the antioxidant activities of the compounds decreased in the order of QT > IR > RT > IRR, while most leukemia cell lines were sensitive to QT and IR with low toxicity towards PBMCs. The reduction of IL-6 and IL-10 secretion by QT and IR was higher than that induced by RT and IRR. The combination of hydrolysis products (QT and IR) possessed a strong synergism in antioxidant, antiproliferative and anti-inflammatory effects, whereas the combination of flavonoid glycosides and their hydrolysis products revealed antagonism. These results suggest that the potential of the combination of hydrolyzed flavonoids from C. johnstonii can be considered as natural compounds for the prevention of cancer.Entities:
Keywords: Cyrtosperma johnstonii; anti-inflammatory; antioxidant; cytotoxicity; flavonoid glycosides; isorhamnetin; quercetin; synergism
Mesh:
Substances:
Year: 2022 PMID: 35630704 PMCID: PMC9146275 DOI: 10.3390/molecules27103226
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1The hydrolysis scheme of flavonoid glycosides (RT and IRR) to obtain their hydrolysis products (QT and IR).
Figure 2Chromatogram of RT (left) and IRR (right) from the extract of C. johnstonii.
Figure 3Chromatogram of standard QT (A), QT hydrolyzed from RT using 0.2 M TFA for 30 min (B), QT hydrolyzed from RT using 2.0 M TFA for 30 min (C), standard IR (D), IR hydrolyzed from IRR using 0.2 M TFA for 30 min (E), and IR hydrolyzed from IRR using 2.0 M TFA for 30 min (F).
The antioxidant activity of a single compound expressed as 50% effective concentration (EC50) and Trolox equivalent antioxidant capacity (TEAC).
| Sample | EC50 (µM) * | TEAC (mM) * |
|---|---|---|
| RT | 386.0 ± 21.4 a | 18.8 ± 4.4 a |
| QT | 78.5 ± 4.8 b | 191.5 ± 15.1 b |
| IRR | 1647.0 ± 109.7 c | 5.94 ± 0.5 c |
| IR | 222.3± 17.0 d | 68.9 ± 7.3 d |
* Difference letters shows statistical significance (p-value < 0.05) in each column.
The combination index (CI) on antioxidant activity in combination.
| Sample | Additional Sample | CI |
|---|---|---|
| QT | RT | 1.13 |
| IR | 0.62 | |
| RT | QT | 1.05 |
| IRR | 0.82 | |
| IR | IRR | 1.32 |
| QT | 0.85 | |
| IRR | IR | 0.88 |
| QT | 1.56 |
Figure 4Dose-response curves between normal cells (PBMCs) viability and RT (A), QT (B), IRR (C), and IR (D).
The cytotoxicity against cancer cells of a single compound expressed as 50% inhibitory concentration (IC50).
| Cancer | Cell Type | IC50 (µM) * | |||
|---|---|---|---|---|---|
| RT | QT | IRR | IR | ||
| Leukemia | EoL-1 | >200.0 a | 6.0 ± 0.1 b | 118.3 ± 20.6 c | 5.3 ± 0.1 d |
| MV4-11 | >200.0 a | 20.4 ± 6.6 b | >200.0 a | 5.9 ± 1.7 c | |
| Molt4 | >200.0 a | 155.3 ± 107.4 a | >200.0 a | >300.0 a | |
| U937 | >200.0 a | 28.8 ± 7.8 b | >200.0 a | >300.0 a | |
| K562 | >200.0 a | 28.7 ± 3.6 b | >200.0 a | 45.9 ± 11.4 c | |
| K562/ADR | >200.0 a | 20.9 ± 3.0 b | >200.0 a | 25.1 ± 7.3 b | |
| Cervical carcinoma | KB-3-1 | >200.0 a | >300.0 a | >200.0 a | 67.5 ± 23.2 b |
| Breast cancer | MCF-7 | >200.0 a | >300.0 a | >200.0 a | >300.0 a |
* Difference letters shows statistical significance (p-value < 0.05) in each row.
The combination index (CI) on cytotoxicity against K562 cells and K562/ADR cells in combination.
| Cell Type | Sample | Additional Sample | CI |
|---|---|---|---|
| K562 | QT | IR | 0.68 |
| IR | QT | 1.14 | |
| K562/ADR | QT | IR | 0.92 |
| IR | QT | 1.22 |
Figure 5Influence of QT, RT, IR and IRR on the secretion of IL-6 (A) and IL-10 (B) as determined by ELISA assays. Different letters show statistical significance (p-value < 0.05).